Inspyr Therapeutics, Inc. Stock Other OTC
Equities
NSPX
US45782A4031
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 241K |
---|---|---|---|---|---|
Net income 2021 | 2M | Net income 2022 | -1M | EV / Sales 2021 | - |
Net cash position 2021 | 197K | Net Debt 2022 | 305K | EV / Sales 2022 | - |
P/E ratio 2021 |
-0.4
x | P/E ratio 2022 |
-0.23
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 16-10-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 08-01-31 | |
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Claire Thomas
BRD | Director/Board Member | 68 | 16-10-11 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |